ScholarLens Back to search
2016•Transplantation and Cellular TherapyOpen access

Basiliximab for the Treatment of Steroid Refractory Acute Graft-Versus-Host-Disease Following Allogeneic Stem Cell Transplantation

Zahra Mahmoudjafari, Joseph P. McGuirk, Siddhartha Ganguly, Omar S. Aljitawi, Tara L. Lin, Anurag K. Singh, Leyla Shune, Sunil Abhyankar

Open full text 1 citations

Abstract

Management of steroid-refractory acute graft versus host disease (GVHD) after allogeneic hematopoietic stem cell transplantation continues to be a major challenge; however, no standard second-line therapy exists. IL2 plays a crucial role in the pathogenesis of acute GVHD. Basiliximab is a chimeric monoclonal antibody that blocks the alpha-chain of the interleukin-2 (IL-2) receptor complex. We report our clinical experience with basiliximab in the second line management of steroid refractory acute GVHD.

Open-access reader

About this research paper

What this paper is about

Management of steroid-refractory acute graft versus host disease (GVHD) after allogeneic hematopoietic stem cell transplantation continues to be a major challenge; however, no standard second-line therapy exists. IL2 plays a crucial role in the pathogenesis of acute GVHD. Basiliximab is a chimeric monoclonal antibody that blocks the alpha-chain of the interleukin-2 (IL-2) receptor complex. We report our clinical experience with basiliximab in the second line management of steroid refractory acute GVHD.

Why it matters

OpenAlex reports 1 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Management of steroid-refractory acute graft versus host disease (GVHD) after allogeneic hematopoietic stem cell transplantation continues to be a major challenge; however, no standard second-line therapy exists. IL2 plays a crucial role in the pathogenesis of acute GVHD. Basiliximab is a chimeric monoclonal antibody that blocks the alpha-chain of the interleukin-2 (IL-2) receptor complex. We report our clinical experience with basiliximab in the second line management of steroid refractory acute GVHD.

Key concepts: Basiliximab, Medicine, Transplantation, Gastroenterology, Refractory (planetary science), Hematopoietic stem cell transplantation, Internal medicine, Immunology

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Basiliximab for the Treatment of Steroid Refractory Acute Graft-Versus-Host-Disease Following Allogeneic Stem Cell Transplantation — Research Paper | ScholarLens